Allogene Therapeutics Inc (Allogene Therapeutics) is a clinical-stage biotechnology company that develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the-shelf allogeneic CAR T therapy candidates for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. It collaborates with other companies for the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
210 East Grand Avenue, South San Francisco, California, 94080
Website
allogene.com
Telephone
1 650 4572700
No of Employees
232
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALLO (NASD)
Revenue (2022)
$95,000
-39.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
3.9%
(2022 vs 2021)
Market Cap*
$585.1M
Net Profit Margin (2022)
XYZ
-57.9%
(2022 vs 2021)
* As of and is in US$
Allogene Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Products |
| Hematological Malignancies: |
| ALLO-501 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company partnered with Arbor Biotechnologies, Inc. to incorporate Arbor's CRISPR gene-editing tech into Allogene's AlloCAR T platform for autoimmune disease treatment. |
| 2024 | Contracts/Agreements | In January, the company and Foresight Diagnostics entered into a partnership to develop a minimal residual disease (MRD) in-vitro diagnostic (IVD) to determine eligibility in ALPHA3. |
| 2022 | Corporate Changes/Expansions | In October, the company's joint venture Allogene Overland Biopharm completed the buildout of its state-of-the-art AlloCAR T manufacturing facility in Shanghai, China. |
Competitor Comparison
| Key Parameters | Allogene Therapeutics Inc | Arvinas Inc | Fate Therapeutics Inc | Lyell Immunopharma Inc | Advanced Biotechnologies Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | New Haven | San Diego | South San Francisco | Eldersburg |
| State/Province | California | Connecticut | California | California | Maryland |
| No. of Employees | 232 | 445 | 181 | 224 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Arie Belldegrun | Chairman | Executive Board | 2017 | 73 |
| David Chang | Chief Executive Officer; President; Director | Executive Board | 2018 | 63 |
| Geoffrey Parker | Chief Financial Officer; Executive Vice President | Senior Management | 2023 | - |
| Stephen Cheng | Chief Information Officer | Senior Management | 2022 | 61 |
| Christine Cassiano | Chief Communications Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward